ADMA Biologics
ADMA
26 hedge funds and large institutions have $68.3M invested in ADMA Biologics in 2015 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 3 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
15% more capital invested
Capital invested by funds: $59.2M → $68.3M (+$9.05M)
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
8% more funds holding
Funds holding: 24 → 26 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SIM
Spark Investment Management
New York
|
+$99K |
| 2 |
CCM
Consonance Capital Management
New York
|
+$70.9K |
| 3 |
WMSA
Weiss Multi-Strategy Advisers
New York
|
+$54K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$21.4K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$18K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$359K |
| 2 |
CA
Commerzbank Aktiengesellschaft
Frankfurt,
Germany
|
-$327K |
| 3 |
Franklin Resources
San Mateo,
California
|
-$81.9K |
| 4 |
Citigroup
New York
|
-$18K |
| 5 |
TI
Telemetry Investments
New York
|
-$17.9K |
ADMA Hedge Fund Activity: Q4 2015 in Review
26 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in ADMA Biologics (ADMA) for Q4 2015, worth a combined $68.3M — up 15% from $59.2M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new ADMA positions and 3 closed out — a net gain of 2 holders — while 8 added to existing stakes and 7 trimmed.
The largest buyer was Spark Investment Management, opening a new position worth an estimated $99K. The largest seller was Alyeska Investment Group, cutting an estimated $359K.
- 26 institutional investors held ADMA Biologics (ADMA) as of Q4 2015, up from 24 in Q3 2015.
- Funds reported $68.3M of ADMA Biologics stock for Q4 2015, up 15% quarter-over-quarter.
- 5 funds opened new ADMA Biologics positions in Q4 2015 and 3 closed out, a net change of +2 holders.
- The largest ADMA Biologics buyer in Q4 2015 was Spark Investment Management, an estimated $99K added.
- The largest ADMA Biologics seller in Q4 2015 was Alyeska Investment Group, an estimated $359K sold.
Based on aggregated 13F filings for Q4 2015.